Micropolis Unveils Next-Gen Robotics, Inks Emirates Steel MoU, and Welcomes UAE Ministers and Royals at Make it in the Emirates 2025
DUBAI, United Arab Emirates, May 22, 2025 (GLOBE NEWSWIRE) -- Micropolis Holding Co. ('Micropolis' or the 'Company') (NYSE: MCRP), a pioneer in unmanned ground vehicles and AI-driven security solutions, unveiled a suite of advanced autonomous systems at Make it in the Emirates 2025, the country's flagship industrial innovation event hosted at Abu Dhabi National Exhibition Centre (ADNEC). All systems are on live display at the Micropolis Pavilion, Booth 6-AM30.
Micropolis presented a trio of advanced robotic platforms addressing critical challenges across environmental recovery, industrial sanitation, and public safety:
The Robotic Forestry Unit, purpose-built for reforestation and ecosystem restoration in areas affected by desertification, wildfires, or climate degradation.
The Box Cleaner, developed in collaboration with MCS Robotics, designed to streamline sanitation in logistics operations while minimizing human risk.
The M01 Patrol Unit, developed for Dubai Police, which continues to represent a milestone in autonomous public safety operations.
The Robotic Forestry Unit is purpose-built to support reforestation and ecosystem rehabilitation in areas affected by desertification, wildfires and other forms of climate-related degradation. The system integrates multiple autonomous components into a single, deployable platform: a ground vehicle for basic plowing and soil conditioning, a drone for aerial seed dispersal over difficult terrain, and a robotic arm for precise placement of nutrients and planting materials. Designed for government and conservation agencies, the platform enables reforestation initiatives in regions that are otherwise inaccessible or economically unfeasible to reach using manual methods.'We're entering an era where ecological restoration can't wait, but it also can't rely solely on manual processes,' said Fareed AlJawhari, CEO of Micropolis Holdings. 'This system allows governments and conservation groups to expand reforestation programs into areas previously considered logistically or economically out of reach. It's a practical application of robotics in service of climate action.'
Also introduced was the Box Cleaner, developed in collaboration with MCS Robotics and engineered to streamline sanitation processes across food-grade and high-throughput industrial logistics. Built on the company's modular M2 platform, the robot eliminates the need for human entry into confined spaces and supports several cleaning methods including dry ice blasting, high-pressure water jets with integrated cleaning agents, and AI-enabled vision systems that detect residue and verify cleaning completion. The unit features onboard tanks for chemicals and waste, allowing for fully autonomous operation as well as remote oversight when needed. The system is designed to help operators reduce cleaning downtime while ensuring food-grade compliance and reducing worker exposure to high-risk tasks.In addition to the two new systems, Micropolis showcased its M01 Patrol Unit, developed for Dubai Police and currently deployed in multiple public safety roles throughout the city. Although not a new product, the M01 drew significant attention at the exhibition due to its real-world operational impact and high degree of autonomy. The patrol unit is equipped with 360-degree AI vision, license plate recognition, autonomous navigation, and crowd-monitoring capabilities, and is designed for use in high-density areas, restricted zones and public infrastructure settings. It can operate independently or be remotely supervised, allowing public safety agencies to increase coverage and responsiveness without adding personnel. The M01 continues to play an integral role in Dubai's smart city and security infrastructure and stands as a mature example of autonomous robotics in civic deployment.During the event, Micropolis signed a Memorandum of Understanding with Emirates Steel (EMSTEEL), a leading UAE-based steel and construction materials manufacturer. The agreement marks the beginning of a collaboration aimed at integrating robotic mobility solutions into EMSTEEL's industrial operations. The partnership reflects both companies' shared commitment to innovation, sustainability and localized technology development, and is expected to explore how autonomous ground vehicles and robotics can enhance safety, efficiency and environmental performance across EMSTEEL's facilities.
Micropolis's participation at Make it in the Emirates 2025 was prominently highlighted by official visits from the nation's top leadership. His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council; His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, and Minister of Defence; His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister, and President of the Presidential Court and His Highness Sheikh Saif bin Zayed Al Nahyan, Deputy Prime Minister, and Minister of Interior visited the Micropolis pavilion, where they were briefed on the Company's latest advancements in autonomous robotics and AI-driven systems. His Excellency Lieutenant General Abdullah Khalifa Al Marri, Commander-in-Chief of Dubai Police, also passed by the stand, further underscoring the event's significance to national leadership. Their presence reflects the UAE's highest-level commitment to fostering innovation, accelerating industrial transformation, and supporting homegrown technologies that contribute to national resilience and global competitiveness. Media coverage of the visit by His Highness Sheikh Khaled was featured by the Abu Dhabi Media Office.
Make it in the Emirates 2025, hosted by the UAE Ministry of Industry and Advanced Technology, brings together leading innovators, manufacturers, and policy-makers to showcase technologies shaping the next era of industrial growth.
About Micropolis Holding Co.Micropolis is a UAE-based company specializing in the design, development, and manufacturing of unmanned ground vehicles (UGVs), AI systems, and smart infrastructure for urban, security, and industrial applications. The Company's vertically integrated capabilities cover everything from mechatronics and embedded systems to AI software and high-level autonomy.For more information please visit www.micropolis.ai.
Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as 'anticipate', 'estimate', 'expect', 'project', 'plan', 'intend', 'believe', 'may', 'will', 'should', 'can have', 'likely' and other words and terms of similar meaning. Forward-looking statements represent Micropolis' current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the 'Risk Factors' section of the registration statement filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Investor Contact:
Media Contact:
KCSA Strategic Communications
Jessica Starman
Valter Pinto, Managing Director
media@elev8newmedia.com
PH: (212) 896-1254
Valter@KCSA.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/acaf7c56-5aef-4384-b4f8-f4ba957f25a1
https://www.globenewswire.com/NewsRoom/AttachmentNg/b8cbc29e-5282-4a35-b97d-2b4c84a0bceb
https://www.globenewswire.com/NewsRoom/AttachmentNg/0556cf3a-1945-4975-b1dd-1f21c04ff992
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
40 Percent of Gamers Wait for Major Discounts - Here's Why That Matters
LONDON, June 03, 2025 (GLOBE NEWSWIRE) -- Digital entertainment marketplace Eneba has revealed a new set of data that provides insight into a new generation of gamers. In their latest survey, 40% of players said that a game only becomes worth buying with a steep discount. As game prices climb, deal-driven consumption is no longer a fringe habit - it's the central force shaping today's $85 billion games market. The Discount Generation It's no longer a niche tactic to look for discounted Steam keys. According to Eneba's survey, 48% of gamers rank price as the most important factor when making a purchase, above other factors like graphics, online reviews, or platform exclusivity. The stereotype of the impulsive gamer chasing the latest AAA release is fading. Instead, a methodical, value-first mindset thrives: wishlists get longer, impulse buys get rarer, and deals dictate demand. This isn't just belt-tightening. As more players jump across PlayStation, Xbox, and PC, 70% say game deals tempt them to be less loyal to any single system. Loyalty is migrating: not to brands, but to bargains. Gamers Take Back Control With platform exclusivity losing its grip, discount culture is democratizing access. Cloud gaming and cross-platform play remove barriers, encouraging players to shop around and compare value. Xbox is already making moves to align itself with this new landscape - sharing its biggest titles, such as Forza Horizon 5, with PlayStation gamers. Publishers who rely on brand allegiance, early hype, or locked ecosystems are up against a consumer base that increasingly waits, compares, and pounces when prices drop. How Eneba Delivers the Value Eneba's strategy isn't about opportunistic sales but about architecting a discount-driven ecosystem. Every element, from Steam keys to subscription discounts, global payment options, and strong buyer protection, is designed for the discerning gamer who won't settle for second-best deals. Eneba is built for everyone seeking accessible and better-priced gaming. As budgets tighten and prices continue to rise, latest research shows that value has shifted from a perk to the baseline, a trend expected to grow. About Eneba Eneba is a digital entertainment marketplace that has served over 15 million buyers. Founded in 2018, Eneba has rapidly grown into a trusted ecosystem for gamers with game keys, gift cards, and mobile top-ups at the best prices, backed by robust customer support and fraud prevention measures. CONTACT: media@
Yahoo
6 minutes ago
- Yahoo
Virtual Private Cloud (VPC) Market to Reach $60 Billion by 2034, Growing at 9% CAGR
Virtual Private Cloud (VPC) Market Report (2025–2034) Luton, Bedfordshire, United Kingdom, June 03, 2025 (GLOBE NEWSWIRE) -- Executive Summary The global Virtual Private Cloud (VPC) market is projected to grow from $25 billion in 2024 to approximately $60 billion by 2034, registering a CAGR of 9% over the forecast period. This growth is primarily driven by the increasing demand for secure, scalable, and customizable cloud solutions across industries. Enterprise demand for advanced cloud infrastructure is rising as businesses strive to optimize costs, enhance data security, and maintain regulatory compliance. The integration of AI, machine learning, and hybrid cloud architectures is accelerating VPC adoption, particularly in sectors like IT, BFSI, and healthcare. Get a Sample PDF Brochure: Key Market Drivers 1. Growing Need for Secure and Scalable Cloud Infrastructure Security as a Priority: As data breaches and ransomware attacks escalate, enterprises demand isolated, secure, and encrypted environments—which VPCs provide through features like network segmentation, firewall rules, and access control. Scalability Benefits: VPCs allow organizations to scale applications and workloads dynamically, without compromising data security or performance. 2. Increasing Compliance with Data Privacy Regulations Regulatory Pressure: Global regulations such as GDPR (Europe), CCPA (California), PDPA (Singapore), and HIPAA (US Healthcare) are compelling enterprises to shift from public to compliance-ready private cloud environments. VPC Advantage: VPCs help enterprises achieve data residency, auditability, and fine-grained policy control, reducing legal risks. 3. Rising Adoption of Hybrid and Multi-Cloud Strategies Enterprises are avoiding vendor lock-in by spreading workloads across different cloud environments. VPCs offer seamless connectivity between public and private clouds, facilitating consistent performance and governance. Hybrid setups also allow latency-sensitive workloads to stay on-premise while leveraging the cloud for elasticity and scale. 4. Integration of AI/ML for Intelligent Data Management Cloud service providers are embedding AI/ML models into VPC environments for: Predictive threat detection Real-time anomaly monitoring Automated resource scaling and performance optimization AI-powered VPCs can automatically flag risks, recommend configurations, and even self-heal networks. 5. Expansion of Remote Work and Collaboration Needs The post-pandemic rise in remote and hybrid workforces has driven the need for secure, anytime-anywhere access to data and applications. VPCs offer VPN-integrated, access-controlled environments suitable for distributed teams and collaboration across geographies. Market Restraints 1. Cloud Security Misconceptions Affecting Adoption Some organizations, especially SMEs and public institutions, still believe public or virtualized cloud environments are inherently unsafe. Lack of awareness of VPC benefits (like isolation, encryption, and auditability) slows market penetration. 2. Vendor Lock-In Concerns Deterring Cloud Transitions Customers are wary of getting tied into proprietary APIs, tools, and pricing models from single cloud vendors. Interoperability limitations and data migration challenges often delay decisions to fully commit to VPC platforms. 3. Supply Chain Volatility Impacting Service Continuity Global chip shortages, geopolitical tensions, and rising energy costs have led to delays in data center expansions and cloud infrastructure upgrades, especially in emerging markets. These disruptions affect VPC service provisioning and long-term cost planning. 4. Price Competition Reducing Provider Margins Intense competition among hyperscalers like AWS, Microsoft Azure, and Google Cloud is compressing margins, especially in emerging regions. Providers are under pressure to offer high-performance VPC solutions at lower costs, limiting investment in innovation and customer support. Browse full Report - Key Market Opportunities 1. Expansion into Healthcare and BFSI with Compliance-Focused VPCs Healthcare (with HIPAA, HL7) and BFSI (with PCI-DSS, SOX, Basel II) demand VPCs with enhanced compliance and audit features. Opportunity to offer industry-specific VPC templates and managed services. 2. Hybrid VPC Solutions Offering Flexibility and Governance Hybrid VPCs (linked to on-premises systems) are ideal for large enterprises seeking gradual migration paths. Providers can capitalize on this by offering connectivity tools (e.g., Direct Connect, Azure ExpressRoute) and policy engines. 3. AI/ML Integration for Predictive Analytics and Automation By embedding machine learning into VPC management consoles, vendors can offer: Forecast-based resource scaling Automated threat detection Data governance recommendations This improves operational efficiency and enhances user experience, especially for enterprises with limited IT staff. 4. Subscription-Based Models Lowering Entry Barriers for SMEs Introducing pay-as-you-go VPC offerings, bundled with cloud credits, support, and basic compliance tools, makes adoption easier for: Startups and SMEs NGOs Academic institutions Opportunity to tap into underserved midmarket segments in Asia-Pacific, LATAM, and MEA. Market Segmentation By Product Type Infrastructure as a Service (IaaS) – Largest share; driven by scalability and cost-effectiveness Platform as a Service (PaaS) – Rapid growth; supports development environments Software as a Service (SaaS) – Expansion fueled by remote collaboration tools By Deployment Model Public VPC – Popular for startups and dynamic scaling Private VPC – Essential for data-sensitive industries (healthcare, BFSI) Hybrid VPC – Rising in demand for operational flexibility By Application Data Storage Disaster Recovery Development and Testing By End User Small & Medium Enterprises (SMEs) – Gaining access to enterprise-grade tools Large Enterprises – Focused on scalability, performance, and compliance By Industry Vertical IT & Telecommunications – Dominant end-user Banking, Financial Services & Insurance (BFSI) – Data protection and compliance Healthcare – Accelerated digital transformation post-pandemic Government, Retail, Manufacturing, and Others By Technology Managed Services Hybrid Cloud By Distribution Channel Direct Sales Online Sales Buy Now : Regional Analysis North America ~40% Market Share | Mature Cloud Ecosystem Key Highlights: Market Maturity: North America, led by the U.S. and Canada, is the most mature market for cloud computing and VPC adoption. Enterprises across sectors have already transitioned large parts of their IT infrastructure to the cloud. Tech Giants & Cloud Leaders: Major cloud providers such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud dominate the VPC space, offering advanced security, scalability, and customization options. Sector Adoption: High adoption in banking, healthcare, government, media, and retail. Heavily regulated industries prefer VPCs for compliance with data security standards (HIPAA, CCPA, etc.). Investment Focus: Emphasis on hybrid and multi-cloud environments, zero-trust architectures, and AI/ML-driven security within VPCs. Market Drivers: Need for data protection and compliance. Cybersecurity threats and ransomware mitigation. Broad 5G rollout supporting cloud-native apps and edge computing. Asia-Pacific (APAC) Fastest-Growing Region | ~12% CAGR (2025–2034) Key Highlights: Rapid Digital Transformation: Governments and enterprises are rapidly modernizing IT infrastructure, especially in India, China, Japan, Australia, and Southeast Asia. Public & Private Sector Demand: VPCs are increasingly used in fintech, healthcare, manufacturing, and smart city projects. Government Initiatives: National programs like Digital India, Smart Nation Singapore, and China's 14th Five-Year Plan promote cloud adoption. Localized Data Centers: Global cloud providers are expanding regional data centers to comply with data residency laws. Market Drivers: Surging internet penetration and mobile usage. Cloud-native startups and SMEs migrating to VPCs. Demand for affordable, scalable, and secure IT infrastructure. Europe Regulatory-Driven Growth | Emphasis on Data Sovereignty Key Highlights: GDPR Compliance: Stringent data privacy regulations (e.g., GDPR) are a key catalyst for VPC adoption, especially in Germany, France, the UK, and the Nordics. Security Focus: Enterprises seek private, encrypted environments for storing and processing sensitive data in sectors like BFSI, public sector, and healthcare. Cloud Sovereignty Projects: Initiatives like GAIA-X (EU's cloud project) encourage VPC deployment within European borders. Market Drivers: Rising demand for cyber-resilient cloud solutions. Support for open-source VPC and cloud platforms. Focus on eco-friendly cloud infrastructure and sustainability. Latin America & Middle East & Africa (MEA) Emerging Markets | Growing Cloud Investments Latin America: Key Countries: Brazil, Mexico, Chile. Growth Factors: Government initiatives to digitize public services and expand cloud usage in education, healthcare, and finance. Infrastructure Challenges: Still addressing bandwidth issues, latency, and data center availability in remote areas. Middle East & Africa (MEA): Key Countries: UAE, Saudi Arabia, South Africa, Kenya. Cloud Expansion: Governments in the UAE and Saudi Arabia are investing in smart governance, e-health, and smart city solutions, driving VPC demand. Data Sovereignty: Emerging regulations are pushing providers to localize cloud infrastructure. Market Drivers: Cost-effective digital transformation. Need for secure platforms for government and financial services. Entry of global cloud players building local partnerships. Major Players Amazon Web Services (AWS) Microsoft Azure Google Cloud Platform IBM Cloud Oracle Cloud Alibaba Cloud VMware Rackspace Technology OVHcloud Linode DigitalOcean Epsilon Telecommunications BMC Software HPE (Hewlett Packard Enterprise) Recent Developments : 1. Amazon Web Services (AWS) In November 2023, AWS introduced enhanced features for its Virtual Private Cloud (VPC) service, focusing on improved network security and streamlined user management. These updates allow users to create multiple isolated networks, facilitating better organization and management of resources. This development underscores AWS's commitment to providing robust and flexible cloud solutions that cater to varying customer needs, particularly in sectors with stringent compliance requirements. 2. Microsoft Azure In October 2023, Microsoft announced a strategic partnership with WSO2 to encourage startups in India to develop cloud-native applications on Microsoft Azure using Choreo, WSO2's cloud-native internal developer platform. This collaboration aims to strengthen the Indian startup ecosystem by providing startups with comprehensive access to cloud-native app development resources, support, and technical expertise. The partnership is set to bring Choreo to the forefront, facilitating the development of innovative solutions tailored to the Indian market. 3. Google Cloud In September 2023, Google Cloud launched a suite of Artificial Intelligence (AI) tools integrated within its Virtual Private Cloud services. This technological advancement enables customers to deploy AI-driven applications seamlessly alongside their existing VPC resources. The integration enhances Google's competitive positioning by combining cloud infrastructure with cutting-edge AI capabilities, which are increasingly critical for businesses aiming to leverage data analytics and machine learning. 4. IBM Cloud In August 2023, IBM announced its expansion into several underserved markets in South Asia with its Virtual Private Cloud offerings. This expansion includes the establishment of localized data centers, adhering to regional data sovereignty laws and ensuring faster access to cloud services. IBM's strategic positioning aims to capture market share in regions where cloud adoption is still nascent, providing compliant and localized services to address regulatory concerns and build trust with potential clients. 5. Oracle Cloud In July 2023, Oracle completed a merger with a prominent Indian cloud solutions provider, enhancing its capabilities within the Indian cloud landscape. This merger allows Oracle to strengthen its competitive position by tapping into the local provider's established customer base and expertise in navigating the regional market. Strategically, this merger signifies a broader trend of consolidation in the cloud market, where companies align to create integrated solutions catering to diverse market segments. This report is also available in the following languages : Japanese (仮想プライベートクラウド市場), Korean (가상 사설 클라우드 시장), Chinese (虚拟私有云市场), French (Marché du cloud privé virtuel), German (Markt für virtuelle private Clouds), and Italian (Mercato del cloud privato virtuale), etc. Get a Sample PDF Brochure: More Research Finding – Cloud Integration Software MarketThe global cloud integration software market is poised to reach approximately $10.5 billion by 2024, driven by escalating demand for seamless connectivity across applications and services. This market is projected to exhibit robust growth, with an estimated value of $24 billion by 2034, reflecting the increasing digital transformation initiatives across various Hybrid Cloud MarketThe hybrid cloud market is expected to grow at 17.0% CAGR from 2023 to 2029. It is expected to reach above USD 205.83 billion by 2029 from USD 50.1 billion in Harnessing the Industrial Cloud Platform MarketThe industrial cloud platform market is poised for significant growth, with an estimated market value of approximately $28 billion in 2024. Forecasts indicate that this value could surge to around $85 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 12.2% over the period from 2025 to Integration Platform as a Service iPaaS MarketThe Global Integration Platform as a Service (iPaaS) market is valued at approximately $8.2 billion, driven by the increasing need for organizational agility and operational efficiency. The market is forecasted to reach around $20.5 billion by 2034, indicating substantial growth U.S. Healthcare Cloud Computing MarketThe U.S. healthcare cloud computing market is valued at approximately $18.5 billion in 2024 and is projected to reach $47.2 billion by 2034, reflecting a robust growth trend. This growth corresponds to a Compound Annual Growth Rate (CAGR) of around 9.6% during the forecast period from 2025 to US Cloud Security MarketThe U.S. cloud security market is valued at approximately $20 billion in 2024, driven by the rising need for data protection and compliance amid increasing cyber threats. With businesses increasingly migrating to cloud platforms, the demand for robust security solutions is surging. The market is projected to reach around $45 billion by 2034, indicating significant growth fueled by digital transformation across US Internet Of Things Cloud Platform MarketThe U.S. Internet of Things (IoT) cloud platform market is poised for significant growth, with an estimated market value of $12 billion in 2024. Forecasts suggest this value will reach approximately $41 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 13% over the forecast period from 2025 to Internet of Things Cloud Platform MarketThe global IoT cloud platform market is projected to reach a value of approximately $75 billion in 2024. With the increasing adoption of connected devices and smart technologies, the market is expected to grow significantly, reaching an estimated $300 billion by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of about 15.5% during the forecast period from 2025 to Everything-as-a-Service MarketThe global Everything-as-a-Service market is anticipated to grow from USD 502.14 Billion in 2024 to USD 2293.71 Billion by 2034, at a CAGR of 18.94% during the forecast period. Bioinformatics Cloud Platform MarketThe bioinformatics cloud platform market is expected to grow at 13.2% CAGR from 2022 to 2029. It is expected to reach above USD 7.39 billion by 2029 from USD 2.42 billion in Cloud Robotics MarketThe Cloud Robotics Market is expected to grow at 25.3% CAGR from 2022 to 2029. It is expected to reach above USD 34.64 billion by 2029 from USD 5.7 billion in Cloud Application MarketThe global cloud computing market size was estimated at USD 380.54 billion in 2020 and is projected to grow USD 1612.04 billion by 2029 at a CAGR of 18.2% during the forecast Cloud Infrastructure Services MarketThe cloud infrastructure services market is expected to grow at 18 % CAGR from 2022 to 2029. It is expected to reach above USD 382.07 billion by 2029 from USD 86.14 billion in Communication Platform as A Service MarketThe communication platform as a service market is expected to grow at 32% CAGR from 2023 to 2029. It is expected to reach above USD 77.61 billion by 2029 from USD 5.98 billion in Cloud Compliance MarketThe global cloud compliance market is valued at approximately $3.5 billion, driven by increasing regulatory demands and the necessity for businesses to manage their data securely across cloud environments. The market is projected to reach about $8.2 billion by 2034, reflecting a robust growth Cloud Infrastructure Entitlement Management CIEM MarketThe Cloud Infrastructure Entitlement Management (CIEM) market is poised for substantial growth, with an anticipated market value of approximately $2 billion in 2024. Projections suggest that the market will expand to around $6 billion by 2034, reflecting increasing demand for security solutions in cloud environments. This trend is fueled by the rising adoption of cloud services across various industries, escalating concerns regarding identity and access management, and the growing prevalence of data Cloud-Based Information Governance marketThe cloud-based information governance market is valued at approximately $10 billion in 2024, driven by the increasing need for data compliance and security across industries. This market is projected to grow significantly, reaching an estimated value of $24 billion by 2034. The forecasted Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is approximately 9.2%. SAAS-Based Business Analytics marketThe global SaaS-based business analytics market is valued at approximately $70 billion in 2024, reflecting a robust demand for data-driven decision-making tools across industries. Analysts project significant growth, forecasting the market will reach around $150 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of approximately 8.1% during the forecast period of Connected Vehicle Cloud MarketThe global Connected Vehicle Cloud market is valued at approximately $12 billion in 2024 and is projected to reach around $37 billion by 2034, reflecting robust growth in the sector. This represents a Compound Annual Growth Rate (CAGR) of approximately 12% during the forecast period from 2025 to Cloud Security Posture Management MarketThe cloud security posture management (CSPM) market is expected to be valued at approximately $3.5 billion in 2024, with a robust growth trajectory projected through the forecast period of 2025 to 2034. By 2034, the market is anticipated to reach around $12 billion, reflecting an impressive compound annual growth rate (CAGR) of approximately 14%, driven by increasing cloud adoption and the growing demand for regulatory CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma
Sustained MRD negativity (10-5) rates at 24 months or longer were more than doubled in transplant eligible patients treated with daratumumab-VRd vs VRd alone in the Phase 3 PERSEUS study1 Data from the Phase 3 CEPHEUS study show daratumumab-VRd significantly reduced the risk of progression or death by 49 percent vs VRd alone in transplant-ineligible newly diagnosed patients2 BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced data from two studies highlighting that DARZALEX® (daratumumab) subcutaneous (SC) formulation with bortezomib, lenalidomide and dexamethasone (daratumumab-VRd) demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1,2 'Daratumumab-based quadruplet regimens are redefining frontline treatment in multiple myeloma, offering the potential for deeper, more durable responses from the start, bringing patients closer to long-term remission,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. 'The latest data presented at ASCO further support the role of the PERSEUS and CEPHEUS regimens as a standard of care in patients with newly diagnosed disease, regardless of transplant eligibility.' A new analysis from the Phase 3 PERSEUS study shows the addition of daratumumab-VRd followed by a maintenance regimen of daratumumab SC with lenalidomide (daratumumab-R), led to improved and deepened rates of overall and sustained MRD negativity (10-5) compared to VRd induction and consolidation with R maintenance.1 At a median follow-up of 47.5 months, sustained MRD negativity (10-5) rates were more than doubled with daratumumab-VRd followed by daratumumab-R maintenance compared to VRd and R maintenance at both 12 months or longer (64.8 percent vs 29.7 percent; odds ratio, 4.42; 95 percent confidence interval [CI], 3.22–6.08; p<0.0001) and 24 months or longer (55.8 percent vs 22.6 percent; odds ratio [OR], 4.36, 95 percent CI, 3.15–6.05, p<0.0001).1 Among patients achieving sustained MRD negativity for 12 months or longer, the 48-month PFS rate for daratumumab-VRd followed by daratumumab-R maintenance was 95.3 percent compared to 94.2 percent for VRd and R maintenance (hazard ratio [HR], 0.83; 95 percent CI,0.3–2.3)—reinforcing the importance of achieving sustained MRD negativity for prolonged disease remission.1 'The data show that daratumumab-VRd followed by a daratumumab-R maintenance regimen is a highly effective treatment option for transplant-eligible patients with newly diagnosed multiple myeloma,' said Philippe Moreau, M.D., head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes, France and presenting author.* 'The depth and durability of MRD negativity observed—paired with high rates of progression-free survival at four years—underscore the long-term benefit the daratumumab SC-based regimen can offer patients early in their treatment journey.' Additional data from Phase 3 CEPHEUS study explore the benefits of daratumumab SC in transplant-ineligible patients across cytogenetic risk status The post-hoc analysis of the Phase 3 CEPHEUS study focused exclusively on transplant-ineligible patients, reinforcing that adding daratumumab SC to VRd significantly deepens response and prolongs PFS compared to VRd alone in this patient population.2 At a median follow-up of 58.7 months, patients receiving daratumumab-VRd achieved markedly higher overall MRD negativity rates at the 10⁻⁵ sensitivity threshold with 60.4 percent vs 39.3 percent with VRd (OR, 2.37; 95 percent CI, 1.47–3.80; p=0.0004).2 Furthermore, treatment with daratumumab-VRd resulted in high MRD-negativity rates at the 10⁻⁶ threshold with 45.8 percent compared to 26.9 percent with VRd (OR, 2.28; 95 percent CI, 1.40–3.73; p=0.0010).2 These deeper responses translated into improved long-term outcomes, with 69.0 percent of patients remaining progression-free at 54-months when treated with daratumumab-VRd vs 48.0 percent with VRd (HR, 0.51; 95 percent CI, 0.35–0.74; p=0.0003).2 Overall survival (OS) numerically favoured daratumumab-VRd (HR, 0.66; 95 percent CI, 0.42–1.03, p=0.0682), with an even greater benefit observed after censoring for COVID-19-related deaths (HR, 0.55; 95 percent CI, 0.34–0.90, p=0.0159).2 Additional data presented at ASCO included a subgroup analysis of the CEPHEUS trial for both transplant-ineligible and deferred NDMM patients who were considered high-risk for cytogenetic abnormalities (Abstract #7529).3 At a median follow-up of 58.7 months, overall MRD negativity rate was improved for patients with standard risk in daratumumab-VRd vs VRd.3 Although rates of MRD negativity by treatment arm in patients with protocol-defined high-risk were comparable, PFS trended toward improvement with daratumumab-VRd.3 'Across multiple studies, the growing body of data on daratumumab-based regimens indicates impressive, deep responses and meaningful progression-free survival in patients with newly diagnosed multiple myeloma, including high-risk,' Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine. 'These consistent results across patient populations, regardless of transplant eligibility, reinforce the role of daratumumab SC as a cornerstone of frontline therapy.' In the PERSEUS and CEPHEUS studies, the safety profiles were consistent with the known safety profile for daratumumab SC.1,2,3 Safety results of daratumumab-VRd in the PERSEUS study were previously reported in The New England Journal of Medicine.4 The most common haematologic adverse reactions (≥20 percent) in patients with multiple myeloma who received daratumumab-VRd vs VRd included neutropenia (69.2 percent vs 58.8 percent), thrombocytopenia (48.4 percent vs 34.3 percent), and anaemia (22.2 percent vs 20.7 percent).4 Similarly, in the CEPHEUS study, daratumumab-VRd showed no additional safety concerns in the transplant-ineligible subgroup compared with the intent to treat population.2 The most common Grade 3/4 haematologic treatment-emergent adverse events (TEAEs) were neutropenia (43.8 percent vs 31.7 percent), thrombocytopenia (30.6 percent vs 23.2 percent) and anaemia (12.5 percent vs 12.7 percent).2 About the PERSEUS and CEPHEUS studiesThe PERSEUS study (NCT03710603) is being conducted in collaboration with the European Myeloma Network as the sponsor.5 PERSEUS is an ongoing, randomised, open-label, Phase 3 study comparing the efficacy and safety of daratumumab, bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) and autologous stem cell transplant (ASCT) followed by D-R maintenance vs standard bortezomib, lenalidomide, and dexamethasone (VRd) and ASCT followed by R maintenance in patients with transplant eligible newly diagnosed multiple myeloma (NDMM) (n=355).4 The primary endpoint is progression-free survival (PFS), and secondary endpoints include overall complete response or better rate, overall minimal residual disease (MRD) negativity (in patients with complete response or better) and overall survival (OS).4 Daratumumab subcutaneous (SC) formulation was discontinued after at least 24 months of D-R maintenance therapy in patients who had a complete response or better and had sustained MRD negative status for at least 12 months.4 The median age is 61.0 (range, 32-70) years for patients in the daratumumab-VRd arm and 59.0 (range, 31-70) years for patients in the VRd arm.4 The study is being conducted in 13 countries in Europe and Australia.5 On 23 October 2024, an indication extension for daratumumab-VRd was approved by the European Commission for NDMM who are eligible for ASCT, based on the results of the PERSEUS study.6,7 CEPHEUS (NCT03652064) is an ongoing, randomised, open-label, Phase 3 study comparing SC daratumumab-VRd with standard VRd.8,9 The trial has enrolled 395 patients with NDMM who are either ineligible for stem cell transplantation (SCT) or for whom SCT is not planned.9 The primary endpoint is overall MRD-negativity rate.9 The minimum age for participation is 18 years for patients in both the daratumumab-VRd arm and VRd arm, with a median patient age of 70 (range 31-80).8 The study is being conducted in 13 countries across North America, South America and Europe.9 On 7 April 2025, an indication extension for daratumumab-VRd was approved by the European Commission for NDMM, based on the results of the CEPHEUS study.9,10 About daratumumab and daratumumab SC Johnson & Johnson is committed to exploring the potential of daratumumab for patients with multiple myeloma across the spectrum of the disease. In August 2012, Janssen Biotech, Inc., a Johnson & Johnson company, and Genmab A/S entered a worldwide agreement, which granted Johnson & Johnson an exclusive licence to develop, manufacture and commercialise daratumumab. Since launch, daratumumab has become a foundational therapy in the treatment of multiple myeloma, having been used in the treatment of more than 618,000 patients worldwide.11 Daratumumab is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma.12 Daratumumab SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.12 CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease.12 Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death.12 Daratumumab may also have an effect on normal cells.12 Data across ten Phase 3 clinical trials, in both the frontline and relapsed settings, have shown that daratumumab-based regimens resulted in significant improvement in progression-free survival and/or overall survival.8,13,14,15,16,17,18,19,20 For further information on daratumumab, please see the Summary of Product Characteristics at: About Multiple MyelomaMultiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.21,22 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications.22 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died.23 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy 24,25 while remissions become progressively shorter.24,25,26 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage.27 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. and profoundly impact health for humanity. Learn more at Follow us at Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. *Philippe Moreau, M.D., head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes, France, has provided consulting, advisory, and speaking services to Janssen-Cilag International NV; he has not been paid for any media work. 1 Moreau P, et al. Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.2 Facon T, et al. Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.3 Bahlis N.J, Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): phase 3 CEPHEUS trial cytogenetic subgroup analysis. Poster presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.4 Sonneveld P, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2024; 390:301-313.5 Daratumumab, VELCADE (bortezomib), lenalidomide and dexamethasone compared to VELCADE, lenalidomide and dexamethasone in subjects with previously untreated multiple myeloma (Perseus). NCT03710603. Available at: Last accessed: May 2025.6 Rodríguez-Otero P, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. 2024 American Society for Clinical Oncology (ASCO) Annual Meeting. June 3, 2024.7 Johnson & Johnson Innovative Medicine EMEA. DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible. Available at: Last accessed: May 2025.8 Usmani S Z, et al. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study. Oral presentation. 21st International Myeloma Society (IMS) Annual Meeting. September 25 – 28, 2024.9 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy. NCT03652064. Available at: Last accessed: May 2025.10 European Commission approves Johnson & Johnson's subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility. Available at: Last accessed: May 2025.11 Johnson & Johnson [data on file]. RF-430506. Number of patients treated with DARZALEX® worldwide as of 30 June 2024.12 Janssen EMEA. European Commission Grants Marketing Authorisation for DARZALEX® (Daratumumab) Subcutaneous Formulation for All Currently Approved Daratumumab Intravenous Formulation Indications. Available at: Last accessed: May 2025.13 Moreau P, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, openlabel, phase 3 study. Lancet 2019;394(10192):29-38.14 Facon T, et al. MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 2019;380(22):2104-2115.15 Mateos MV, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. The Lancet 2020;395:P132-141.16 Dimopoulos MA, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(6):801-812.17 Palladini G, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020;2;136(1):71-80.18 Chari A, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130(8):974-981.19 Bahlis NJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34(7):1875-1884.20 Mateos MV, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020;20(8):509-518.21 Abdi J, et al. Drug resistance in multiple myeloma: latest findings on molecular mechanisms. Oncotarget 2013;4(12):2186-2207.22 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: Last accessed: May 2025.23 ECIS - European Cancer Information System. Estimates of cancer incidence and mortality in 2022, by country. Multiple myeloma. Available at: Last accessed: May 2025.24 Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347.25 Hernández-Rivas JÁ, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23.26 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430.27 American Cancer Society. Multiple myeloma: early detection, diagnosis and staging. Available at: Last accessed: May 2025. CP-520659 May 2025 CONTACT: Media contact: Jenni Mildon jmildon@ +44 7920 418 552 Investor contact: Lauren Johnson investor-relations@
